Differences in presentation of younger and older systemic sclerosis patients in clinical trials

Clinical and Experimental Rheumatology

Volumn 28, Issue 5 SUPPL. 62, 2010, Pages

  Weng, H H ^a,b   Ranganath, V K ^b   Oh, M ^b,c   Park, G S ^a,b   Khanna, D ^b   Clements, P J ^b   Seibold, J R ^d   Elashoff, D A ^b   Furst, D E ^b  

^a AMGEN INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BAXTER HEALTHCARE CORPORATION   (United States)

^d UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Age; Scleroderma; Systemic sclerosis

Indexed keywords

ACETYLSALICYLIC ACID; ALKALINE PHOSPHATASE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ASPARTATE AMINOTRANSFERASE; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CREATINE KINASE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PLACEBO; RELAXIN;

ADULT; AGE DETERMINATION; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DEMOGRAPHY; DIASTOLIC BLOOD PRESSURE; DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS; DISEASE DURATION; FEMALE; GROUPS BY AGE; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; SYSTEMIC SCLEROSIS;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; BLOOD PRESSURE; CLINICAL CHEMISTRY TESTS; CREATINE KINASE; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; SCLERODERMA, DIFFUSE; SEVERITY OF ILLNESS INDEX; SKIN; YOUNG ADULT;

EID: 78650578426     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. TASHKIN DP, ELASHOFF R, CLEMENTS PJ et al.: Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66.
2. KHANNA D, CLEMENTS PJ, FURST DE et al.: Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2009;60:1101-11.
3. CZIRJAK L, NAGY Z, SZEGEDI G: Systemic sclerosis in the elderly. Clin Rheumatol 1992;11:483-85.
4. BARNETTAJ: Scleroderma (Progressive Systemic-Sclerosis)-Progress and course based on a personal series of 118 cases. Med J Australia 1978;2:129-34.
5. MEDSGER TA JR, MASI AT, RODNAN GP, BENEDEK TG, ROBINSON H: Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med 1971;75:369-76.
6. WYNN J, FINEBERG N, MATZER L et al.: Prediction of survival in progressive systemic sclerosis by multivariate analysis of clinical features. Am Heart J 1985;110:123-27.
7. KARASSA FB, IOANNIDIS JP: Mortality in systemic sclerosis. Clin Exp Rheumatol 2008;26(Suppl. 51):S85-93.
8. SCALAPINO K, ARKACHAISRI T, LUCAS M et al.: Childhood onset systemic sclerosis: Classification, clinical and serologic features, and survival in comparison with adult onset disease. J Rheumatol 2006;33:1004-13.
9. CLEMENTS PJ, FURST DE, WONG WK et al.: High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis-Analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999;42:1194-203.
10. POSTLETHWAITE AE, WONG WK, CLEMENTS P et al.: A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: 1. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. Arthritis Rheum 2008;58:1810-22.
11. POPE JE, BELLAMY N, SEIBOLD JR et al.: A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001;44:1351-58.
12. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
13. LEROY EC, MEDSGER TA Jr: Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573-76.
14. FURST DE, CLEMENTS PJ, STEEN VD et al.: The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 1998;25:84-8.
15. FRIES JF, SPITZ P, KRAINES RG, HOLMAN HR: Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
16. LITTELL, RC, MILLIKEN GA, STROUP, WW, WOLFINGER, RD: SAS System for Mixed Models. 6th ed. 2006 SAS Institute Ref Type: Serial (Book, Monograph)
17. http://www.cdc.gov/nchs/nhanes.htm 2006; Ref Type: Data File.
18. KRISHNAN E, SOKKA T, HAKKINEN A, HUBERT H, HANNONEN P: Normative values for the Health Assessment Questionnaire disability index: benchmarking disability in the general population. Arthritis Rheum 2004;50:953-60.
19. MELTZER HY: Factors affecting serum creatine phosphokinase levels in the general population: the role of race, activity and age. Clin Chim Acta 1971;33:165-72.
20. NETER J, KUTNER MH, WASSERMAN W, NACHTSHEIM CJ: Applied linear regression models. 3rd ed. Chicago: Irwin, 1996.
21. WALKER UA, TYNDALL A, CZIRJAK L: et al.: Clinical risk assessment of organ manifestations in systemic sclerosis - a report from the EULAR Scleroderma Trials And Research (EUSTAR) group data base. Ann Rheum Dis 2007.
22. MAYES MD, LACEY JV JR, BEEBE-DIMMER J et al.: Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003;48:2246-55.
23. KRISHNAN E, FURST DE: Systemic sclerosis mortality in the United States: 1979-1998. Eur J Epidemiol 2005;20:855-61.
24. KUWANA M, KABURAKI J, ARNETT F, HOWARD RF, MEDSGER TA, WRIGHT TM: Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody. Arthritis Rheum 1999;42:465-74.
25. MIMURA Y, IHN H, JINNIN M, ASANO Y, YAMANE K, TAMAKI K: Clinical and laboratory features of scleroderma patients developing skeletal myopathy. Clin Rheumatol 2005;24:99-102.